Across TCGA pan-cancer cohorts, KRCC1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated KRCC1 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher KRCC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRCC1 expression acts as an unfavorable survival marker.
OV are the cancer types where KRCC1 Mutation most reproducibly stratifies survival.